Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051289 | 0.93 | NAMPT (0.50) | NAMPTPOLBRAB9AKMT2AMEN1 | |
| SCHEMBL3058637 | 0.93 | POLB (0.58) | NAMPTPOLBL3MBTL1KMT2AMEN1 | |
| SCHEMBL3044935 | 0.91 | NAMPT (0.55) | NAMPTPOLBRAB9ANPC1L3MBTL1 | |
| SCHEMBL3045301 | 0.89 | POLB (0.51) | NAMPTPOLBKMT2AMEN1 | |
| SCHEMBL3042684 | 0.89 | POLB (0.54) | NAMPTPOLBKMT2AMEN1 | |
| SCHEMBL3054341 | 0.89 | POLB (0.56) | NAMPTPOLBKMT2AMEN1 | |
| SCHEMBL3052786 | 0.87 | POLB (0.53) | NAMPTPOLBKMT2AMEN1 | |
| SCHEMBL3060592 | 0.87 | POLB (0.55) | NAMPTPOLBL3MBTL1KMT2AMEN1 | |
| SCHEMBL3055841 | 0.87 | POLB (0.55) | NAMPTPOLBKMT2AMEN1 | |
| SCHEMBL3052906 | 0.85 | POLB (0.58) | NAMPTPOLBL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | claimed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| EP-2205566-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009074749-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | NAMPT 2/4885POLB 1463/4885RAB9A 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.